Guillain-Barré syndrome: incidence and mortality rates in US hospitals
- PMID: 18443311
- DOI: 10.1212/01.wnl.0000310983.38724.d4
Guillain-Barré syndrome: incidence and mortality rates in US hospitals
Abstract
Objective: To determine the incidence, in-hospital mortality, and predictors of death in Guillain-Barré syndrome (GBS) in a large US cohort.
Methods: Our cohort was identified from the Nationwide Inpatient Sample database, 2000 through 2004. We excluded patients younger than 18 years and those who presented with rapidly paralyzing conditions due to other causes. GBS patients who were transferred between hospitals were counted once. The incidence rate adjusted for 20% of the US census reported by the Census Bureau. A logistic regression model was used to identify predictors of death.
Results: After data cleansing, 4,954 patients were identified with a primary diagnosis of GBS. The adjusted incidence rate varied between 1.65 and 1.79 per 100,000 during the years included in this study. The in-hospital mortality rate was 2.58% (128/4,954) and did not change significantly over the study period. Eleven percent had variable pulmonary complications, and 9.1% received endotracheal intubation, which was a predictor of mortality (adjusted odds ratio 5.09, 95% CI 3.21-8.05). Other predictors of mortality included older age, composite comorbidity index, cardiac complications, and sepsis.
Conclusion: The mortality rate in Guillain-Barré syndrome is low, and predictors of death are similar to those predicting poor disability outcome. The disease incidence was stable over the 5 years included in this study.
Similar articles
-
Immunotherapy for Guillain-Barré syndrome in the US hospitals.J Clin Neuromuscul Dis. 2008 Sep;10(1):4-10. doi: 10.1097/CND.0b013e318182b5ce. J Clin Neuromuscul Dis. 2008. PMID: 18772694
-
Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals.Neurology. 2009 May 5;72(18):1548-54. doi: 10.1212/WNL.0b013e3181a41211. Neurology. 2009. PMID: 19414721
-
In-hospital mortality of generalized convulsive status epilepticus: a large US sample.Neurology. 2007 Aug 28;69(9):886-93. doi: 10.1212/01.wnl.0000269791.96189.70. Neurology. 2007. PMID: 17724291
-
[Guillain-Barré syndrome in the northern area of Gran Canaria and the island of Lanzarote].Rev Neurol. 2002 Oct 16-31;35(8):705-10. Rev Neurol. 2002. PMID: 12402219 Review. Spanish.
-
Neuromuscular disease causing acute respiratory failure.Respir Care. 2006 Sep;51(9):1016-21; discussion 1021-3. Respir Care. 2006. PMID: 16934165 Review.
Cited by
-
U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines.Vaccine. 2021 Jun 23;39(28):3666-3677. doi: 10.1016/j.vaccine.2021.05.016. Epub 2021 May 14. Vaccine. 2021. PMID: 34088506 Free PMC article. Review.
-
Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study.Crit Care. 2011 Jul 11;15(4):R164. doi: 10.1186/cc10305. Crit Care. 2011. PMID: 21745374 Free PMC article. Clinical Trial.
-
Incidence and prevalence of CIDP and the association of diabetes mellitus.Neurology. 2009 Jul 7;73(1):39-45. doi: 10.1212/WNL.0b013e3181aaea47. Neurology. 2009. PMID: 19564582 Free PMC article.
-
Immunotherapy of Guillain-Barré syndrome.Hum Vaccin Immunother. 2018;14(11):2568-2579. doi: 10.1080/21645515.2018.1493415. Epub 2018 Jul 12. Hum Vaccin Immunother. 2018. PMID: 29953326 Free PMC article. Review.
-
Zika and dengue but not chikungunya are associated with Guillain-Barré syndrome in Mexico: A case-control study.PLoS Negl Trop Dis. 2020 Dec 17;14(12):e0008032. doi: 10.1371/journal.pntd.0008032. eCollection 2020 Dec. PLoS Negl Trop Dis. 2020. PMID: 33332366 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical